Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors [1] Summary by Relevant Sections Allegations - The class action complaint alleges that during the Class Period from August 5, 2021, to November 29, 2023, BioVie made materially false and misleading statements and failed to disclose adverse facts about its business and operations [2] - Specific allegations include: - Lack of proper oversight of the Phase 3 clinical trial [2] - Negative impact of the COVID-19 pandemic on the trial's oversight [2] - Increased risk of unreliable data due to reliance on contract research organizations, leading to significant patient exclusions from the trial [2] - Failure of the Phase 3 clinical trial to meet its primary endpoints due to these exclusions [2] - Misleading statements regarding BioVie's business, operations, and compliance with current good clinical practices [2] Contact Information - Long-term stockholders of BioVie are encouraged to reach out for more information regarding the claims or their rights [3] - Contact can be made via email or telephone, with no cost or obligation to the stockholders [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in various complex litigations across state and federal courts [4]

Financial Performance - The net loss for the three months ended September 30, 2024, was approximately $4.2 million, a decrease of $6.5 million compared to a net loss of $10.7 million for the same period in 2023[123]. - Total operating expenses for the three months ended September 30, 2024, were approximately $4.1 million, down from $10.9 million in the same period in 2023, reflecting a decrease of approximately $6.8 million[124]. - Research and development expenses were approximately $2.0 million for the three months ended September 30, 2024, a decline of approximately $6.9 million from $8.9 million for the same period in 2023[125]. - As of September 30, 2024, the Company had working capital of approximately $13.3 million and cash and cash equivalents totaling approximately $20.0 million[131]. - The Company has not generated any revenue and does not expect to do so in the foreseeable future, relying on ongoing development and financing efforts[133]. Clinical Trials and Drug Development - The Phase 2 study of bezisterim (NE3107) for Parkinson's disease was completed in December 2022, with both primary and secondary objectives met[114]. - The Company received a clinical trial award of up to $13.1 million from the U.S. Department of Defense to evaluate bezisterim (NE3107) for long COVID, with trials expected to commence by early 2025[116]. - BIV201, an investigational drug for liver disease, showed a 53% reduction in ascites fluid for patients who completed treatment, sustained at a 43% reduction over three months post-treatment[119]. - The FDA has granted Fast Track and Orphan Drug status to BIV201, which is being evaluated for the treatment of ascites due to chronic liver cirrhosis[117]. - The Company anticipates finalizing protocol designs for the Phase 3 study of BIV201 following guidance from the FDA regarding clinical testing[120]. Capital Raising Activities - During the three months ended September 30, 2024, the Company sold approximately 2,143 shares of Common Stock for total net proceeds of approximately $6,400 after commissions and offering costs[135]. - The Company closed a public offering on September 25, 2024, of 1,360,800 shares at a combined public offering price of $1.53 per share, generating gross proceeds of approximately $3.0 million before expenses[136]. - In October 2024, the Company closed three registered direct offerings totaling 8,256,000 shares, with gross proceeds of approximately $15.9 million before expenses[137]. - The October Common Warrants have exercise prices ranging from $1.37 to $2.83 per share and are exercisable beginning six months following issuance[137]. - The Company issued placement agent warrants in the October Offerings to purchase 412,800 shares of Common Stock at prices ranging from $1.88 to $3.54 per share[137]. - The September Common Warrants have an exercise price of $1.53 per share and are immediately exercisable upon issuance[136]. - The Company incurred offering expenses of approximately $747,000 for the September 2024 Offering and approximately $2.8 million for the October Offerings[136][137]. - The September Placement Agent's Warrants are exercisable at a price of $1.91 per share, equal to 125% of the public offering price[136]. Accounting Policies - The Company added a Grant Program accounting policy for the three-month period ended September 30, 2024, with no other significant changes to critical accounting policies[138]. - The Company determined that recent accounting pronouncements are either not applicable or expected to have minimal impact on financial statements[139].

Core Viewpoint - BioVie Inc. has announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about October 29, 2024, pending customary closing conditions [2]. - ThinkEquity is acting as the sole placement agent for this offering [2]. - The shares are being offered under a shelf registration statement filed with the SEC, which became effective on August 28, 2023 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital and general corporate purposes [2]. Group 3: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for chronic conditions, including neurological disorders and liver disease [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in Alzheimer's disease and Parkinson's disease [5]. - BioVie’s orphan drug candidate BIV201 is under evaluation for treating liver cirrhosis and ascites, with FDA Fast Track status [5].

CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3 ...

CARSON CITY, Nev., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share. In a concurrent private placem ...

Core Viewpoint - BioVie Inc. has announced a registered direct offering of 4,443,000 shares of its common stock at a price of $1.50 per share, aiming to raise approximately $6.66 million before expenses [1][2]. Group 1: Offering Details - The offering includes unregistered warrants for investors to purchase an equal number of shares at an exercise price of $1.37, exercisable six months post-issuance and expiring five years later [1][2]. - The expected closing date for the offering is around October 22, 2024, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be allocated for working capital and general corporate purposes [2]. Group 3: Company Overview - BioVie Inc. is focused on developing innovative drug therapies for chronic conditions, including neurological disorders like Alzheimer's and Parkinson's, as well as advanced liver disease [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in neurodegenerative diseases [5]. - BioVie’s orphan drug candidate BIV201 is under FDA Fast Track status and is being prepared for Phase 3 clinical testing to address liver cirrhosis complications [5].

Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets Liquid formulation has demonstrated room-temperature stability for up to 24 months, representing an important advantage for treating patients with cirrhosis and ascites in the home-care setting CARSON, Nev., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, $0.0001 par value per share BIVI The NASDAQ Stock Market, LLC FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ ...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday. The Dow traded down 0.04% to 42,109.03 while the NASDAQ rose 0.51% to 18,065.98. The S&P 500 also rose, gaining, 0.14% to 5,726.56. Check This Out: How To Earn $500 A Month From Nvidia Stock Leading and Lagging Sectors Materials shares jumped by 1.2% on Tuesday. In trading on Tuesday, financials shares fell by 1.1%. Top Headline Thor Industries, Inc. THO reported better-than-exp earnings for its fourth quar ...

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accompanying common stock purchase warrants in a best efforts public offering. All of the shares ...